Mirum Pharmaceuticals Financial Statements
NASDAQ: MIRMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Mirum Pharmaceuticals revenue and earnings
In fiscal 2025, Mirum Pharmaceuticals generated $521.3 million in revenue, up 54.7% from fiscal 2024, its 5th consecutive year of revenue growth. Mirum Pharmaceuticals reported a net loss of $23.4 million, compared with a loss of $87.9 million a year earlier. Operating margin was -4.2%.
Diluted earnings per share came in at -$0.47.
Summary generated from market data by MetaCap's automated system. Methodology
Mirum Pharmaceuticals income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Revenue | 521.31M | 336.89M | 186.37M | 77.06M | 19.14M | 0 | — |
| Revenue growth (YoY) | +54.74% | +80.76% | +141.85% | +302.66% | — | — | — |
| Operating Expenses | 543.45M | 424.49M | 295.53M | 208.28M | 192.55M | 104.30M | 54.74M |
| Research & Development | 186.18M | 140.63M | 102.61M | 106.84M | 131.43M | 81.61M | 42.99M |
| Selling, General & Admin | 257.03M | 202.22M | 145.88M | 89.07M | 59.22M | — | — |
| Operating Income | -22.14M | -87.61M | -109.15M | -131.22M | -173.41M | -104.30M | -54.74M |
| Interest Expense | 14.39M | 14.31M | 15.11M | 15.98M | — | — | — |
| Other Income (Expense) | 2.37M | 1.21M | -2.82M | 365.00K | -582.00K | -192.00K | -21.00K |
| Pretax Income | -21.43M | -86.91M | -162.42M | -142.07M | -83.95M | -103.26M | -52.53M |
| Income Tax | 1.94M | 1.03M | 991.00K | -6.41M | 37.00K | 6.00K | 21.00K |
| Net Income | -23.36M | -87.94M | -163.41M | -135.66M | -83.99M | -103.27M | -52.55M |
| Net Income growth (YoY) | — | — | — | — | — | — | — |
| EPS (Basic) | -0.47 | -1.85 | -4.00 | -4.01 | -2.77 | -4.09 | -4.58 |
| EPS (Diluted) | -0.47 | -1.85 | -4.00 | -4.02 | -2.77 | -4.09 | -4.58 |
| Shares Outstanding (Basic) | 50.20M | 47.52M | 40.89M | 33.84M | 30.32M | 25.25M | 11.49M |
| Shares Outstanding (Diluted) | 50.20M | 47.52M | 40.89M | 33.98M | 30.32M | 25.25M | 11.49M |
| EBITDA | 2.11M | -63.98M | -98.33M | -127.98M | -172.82M | -103.99M | -54.60M |
| Operating Margin | -4.25% | -26.00% | -58.57% | -170.28% | -906.12% | — | — |
| Net Margin | -4.48% | -26.10% | -87.68% | -176.05% | -438.85% | — | — |
This table shows 7 annual periods of Mirum Pharmaceuticals's income statement, from FY 2025 back to FY 2019, across 17 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow MIRM's reporting calendar. What is a income statement?